Market Trading Guide: Akums Drugs Among 4 Stock Recommendations for Thursday

Why It Matters

These breakout setups suggest near‑term upside that can offset broader market weakness, offering investors tactical entry points ahead of the Fed‑influencing CPI release.

Key Takeaways

• Akums Drugs trades ~$7, target $7.5‑$8 after breakout.
• Aditya Birla Sun Life AMC at $13.4, target $14.1‑$14.7.
• HSCL FY26 profit ₹751 cr ≈ $90 M, EBITDA > $12 M.
• RateGain recovers to $9.4, trading above 50‑day EMA.
• Indian market dips ahead of US inflation, but select stocks rally

Pulse Analysis

Domestic equity indices slipped on Tuesday as investors priced in global uncertainty and awaited the U.S. Consumer Price Index release, which could steer Federal Reserve policy. The rupee‑linked market fell roughly 0.4%, mirroring a modest pull‑back in oil‑related stocks despite steady crude prices. Yet the slowdown was uneven; fast‑moving consumer goods outperformed on anticipated price hikes, while private‑bank shares gained after the RBI relaxed FCNR(B) and ECB limits. The backdrop underscores how macro data continues to dominate short‑term sentiment in Indian equities.

Against that backdrop, technical analysts highlighted two clear winners. Akums Drugs, trading around $7 per share, shattered the ₹550‑₹560 (≈ $6.6‑$6.7) resistance zone with volume‑driven momentum, staying above its 20‑, 50‑, 100‑ and 200‑day EMAs and pushing the RSI past 70. The firm set a price target of $7.5‑$8, suggesting a near‑term upside of roughly 12‑15%. Similarly, Aditya Birla Sun Life AMC traded at $13.4, comfortably above its 20‑day EMA, and analysts projected a target range of $14.1‑$14.7, reflecting a 5‑10% gain. Both stocks exhibit classic breakout patterns that often precede sustained rallies.

The guide also flagged Himadri Speciality Chemical and RateGain as high‑conviction buys. HSCL reported FY26 profit of ₹751 crore (≈ $90 million) and EBITDA crossing the ₹1,000 crore ($12 million) threshold, while pivoting toward EV‑grade chemicals—a sector poised for rapid growth as India expands its electric‑vehicle ecosystem. RateGain, now at $9.4, completed a V‑shaped recovery and sits above key moving averages, confirming a Stage 2 uptrend. For investors, these picks illustrate how disciplined technical screening can uncover opportunities even when broader markets are jittery.